Key facts
- It has raised $362.5M across 2 recorded rounds; the latest was Later Stage VC (Series D) ($181.4M) in Nov 2024.
- Notable investors include Bpifrance, RA Capital Management, High-Tech Gründerfonds, OrbiMed, Kinled Holding — 21 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 21 names
- ·Watchlist + deal alerts for Alentis Therapeutics
Funding rounds
2 roundsAbout Alentis Therapeutics
Operator of a clinical-stage biopharmaceutical company intended to offer various treatments for cancer and fibrotic diseases. The company develops innovative therapies for the treatment of cancer and other serious diseases, targeting immune checkpoints and modulating the immune system to enhance its ability to fight tumors, enabling medical researchers to treat liver fibrosis, cirrhosis, and liver cancer in patients.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Allschwil, Switzerland
- Founded
- 2019
- Employees
- 66
- Website
- alentis.ch/
- Ownership
- Privately Held (backing)
Alentis Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Alentis Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Alentis Therapeutics in its N-PORT filings yet. We sweep new filings monthly.